[
  {
    "ts": null,
    "headline": "Allison Worldwide and Stagwell (STGW) Bolster Communications and Healthcare Capabilities in Naming Wendy Lund as Global CEO, Allison and Stagwell's Vice Chair of Health",
    "summary": "NEW YORK CITY, NEW YORK / ACCESS Newswire / January 6, 2026 / Allison Worldwide and Stagwell (NASDAQ:STGW) are turbocharging their global communications capabilities and positioning for growth in healthcare with the appointment of industry veteran ...",
    "url": "https://finnhub.io/api/news?id=9ceca98167f74cd297591a9c2a900c81a39560162c7340b96da8b330055192dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767718800,
      "headline": "Allison Worldwide and Stagwell (STGW) Bolster Communications and Healthcare Capabilities in Naming Wendy Lund as Global CEO, Allison and Stagwell's Vice Chair of Health",
      "id": 138001977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "NEW YORK CITY, NEW YORK / ACCESS Newswire / January 6, 2026 / Allison Worldwide and Stagwell (NASDAQ:STGW) are turbocharging their global communications capabilities and positioning for growth in healthcare with the appointment of industry veteran ...",
      "url": "https://finnhub.io/api/news?id=9ceca98167f74cd297591a9c2a900c81a39560162c7340b96da8b330055192dd"
    }
  },
  {
    "ts": null,
    "headline": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
    "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
    "url": "https://finnhub.io/api/news?id=0d74f9a697e32e7a858275c83749048028e8ce379b5ff188ab9702c77d3cab2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708780,
      "headline": "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines",
      "id": 138000160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The \"TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook",
      "url": "https://finnhub.io/api/news?id=0d74f9a697e32e7a858275c83749048028e8ce379b5ff188ab9702c77d3cab2a"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=e677a46a5d07f70e9e83092c41df640db2c745dccf279456838870f2d8aa628f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708006,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 138001978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=e677a46a5d07f70e9e83092c41df640db2c745dccf279456838870f2d8aa628f"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co.'s Q4 2025 Earnings: What to Expect",
    "summary": "Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.",
    "url": "https://finnhub.io/api/news?id=b347c2550a0b0a5b642c507efd475cd4addd853db9ad6ac825dc6edd069a90a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767699391,
      "headline": "Merck & Co.'s Q4 2025 Earnings: What to Expect",
      "id": 138000609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.",
      "url": "https://finnhub.io/api/news?id=b347c2550a0b0a5b642c507efd475cd4addd853db9ad6ac825dc6edd069a90a2"
    }
  },
  {
    "ts": null,
    "headline": "BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)",
    "summary": "BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...",
    "url": "https://finnhub.io/api/news?id=48ad16b50754f5060678e9359e4dbe2c413582a117b8d048b00cefd53ff68c15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767673617,
      "headline": "BioInvent–KEYTRUDA Ovarian Cancer Signal Could Be A Game Changer For Merck (MRK)",
      "id": 137997799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...",
      "url": "https://finnhub.io/api/news?id=48ad16b50754f5060678e9359e4dbe2c413582a117b8d048b00cefd53ff68c15"
    }
  }
]